Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

108.74 -0.13 (-0.12%)
Streaming Delayed Price Updated: 3:21 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
From Merck & Co., Inc.
Via Business Wire
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies. 
Via The Motley Fool
Topics Energy Stocks
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.
From Merck Sharp & Dohme
Via Business Wire
News headline image
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
News headline image
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
News headline image
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
News headline image
Merck Q3 2025 Earnings Call Transcript ↗
Merck Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
News headline image
Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook ↗
Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid mixed product performance. 
Via Benzinga
News headline image
Merck’s (NYSE:MRK) Q3 Sales Top Estimates
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to be... 
Via StockStory
News headline image
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
News headline image
Merck & Co. Inc. (NYSE:MRK) Q3 2025 Earnings Beat Expectations Despite Stock Decline ↗
Merck Q3 2025 earnings beat estimates with strong sales and EPS growth, driven by KEYTRUDA and WINREVAIR, yet shares fell on guidance. 
Via Chartmill
Topics Earnings
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain ↗
The company sells a notable vaccine to prevent human papillomavirus. But sales are struggling. 
Via Investor's Business Daily
Topics Earnings Stocks
News headline image
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via Investor Brand Network
News headline image
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)
From Merck & Co., Inc.
Via Business Wire
News headline image
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Merck (MRK) Reports Earnings Tomorrow: What To Expect
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Looking At Merck & Co's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer ↗
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer. 
Via Benzinga
News headline image
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
News headline image
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Dividend-Paying Drug Stocks to Buy at a Discount ↗
Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying? 
Via The Motley Fool
Topics Intellectual Property
News headline image
How Is The Market Feeling About Merck & Co Inc? ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.